Abstract
Purpose of Review: This review discusses the interplay between coronavirus disease 2019 (COVID-19, caused by SARS-CoV-2 infection), diabetes mellitus, and hyperglycemia in the hospital setting. There are data emerging about diabetes and hyperglycemia, their prevalence, and potential risks in the setting of SARS-CoV-2 infection and COVID-19. Recent Findings: It is known that viral infections exert effects on beta cell function and insulin resistance. Therefore, much can be learned about SARS-CoV-2/COVID-19 from examining these known relationships. Such pathophysiological underpinnings may unlock greater understanding as we navigate atypical cases of hyperglycemia, severe insulin resistance, and diabetic ketoacidosis amidst COVID-19. Glycemic outcomes likely have beneficial effects on morbidity and mortality, but this needs to be studied. Summary: Changes in diabetes-related protocols and new technology can be deployed in the inpatient setting to potentially improve healthcare worker and patient safety; however, one must weigh the risks and benefits of implementation during a pandemic. Ultimately, knowledge and research must be shared at record speed to combat this global crisis.
Original language | English (US) |
---|---|
Article number | 77 |
Journal | Current diabetes reports |
Volume | 20 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2020 |
Funding
Amisha Wallia is a section editor for Current Diabetes Reports and recieves grant funding from Novo Nordisk, and research salary support from United Health Group and Eli Lilly. Grace Prince, Emilie Touma, and Malek El Muayed each declare no potential conflicts of interest. Jane Jeffrie Seley is a section editor for Current Diabetes Reports.
Keywords
- Covid-19
- Diabetes
- Hyperglycemia
- Inpatient management
- SARS-CoV2
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism